netFormulary NHS
North Staffordshire Joint Formulary
North Staffordshire Clinical Commissioning Group
Stoke-on-Trent Clinical Commissioning Group
 Search
 Formulary Chapter 12: Ear, nose and oropharynx - Full Chapter
12.02.01  Expand sub section  Drugs used in nasal allergy
12.02.01  Expand sub section  Antihistamines
12.02.01  Expand sub section  Corticosteroids
Beclometasone dipropionate
(nasal spray)
View adult BNF View SPC online View childrens BNF  Track Changes
First Choice
Green

Beclometasone dipropionate 50microgram/dose nasal spray

1st line for the treatment and prophylaxis of allergic perennial rhinitis

Self Care Self Care Medicine- Available OTC for self-care for adults over 18s

 

 
Fluticasone furoate
(Avamys)
(nasal spray)
View adult BNF View SPC online View childrens BNF  Track Changes
Second Choice
Green

Avamys®- Fluticasone furoate 27.5microgram/dose nasal spray

2nd line for the treatment and prophylaxis of allergic perennial rhinitis

 

 
   
Mometasone furoate 
View adult BNF View SPC online View childrens BNF  Track Changes
Second Choice
Green

Mometasone furoate 50microgram/dose nasal spray

2nd line for the treatment and prophylaxis of allergic perennial rhinitis.
Recommendation: Licensed for the treatment of nasal polyps

 

 
   
Budesonide (Rhinocort Aqua)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Budesonide 64microgram/dose nasal spray

Recommendation: Licensed for the treatment of nasal polyps

Rhinocort Aqua® is not licensed for use in children (but generic products are).

 
   
Fluticasone with azelastine
(Dymista)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Dymista®- Fluticasone propionate 50microgram/dose & azelastine hydrochloride 137microgram/dose nasal spray.

2nd line for moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or intranasal glucocorticoid is insufficient.

 

 
   
12.02.01  Expand sub section  Cromoglicate
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG
Blueteq
High Cost Drug Approval System

Traffic Light Status Information

Status Description

Red

Medicines that can only be prescribed within Secondary Care. Examples of medicines which fall into this category are: Certain new medicines and new indications for older medicines where there is at present no experience of use in Primary Care. Medicines or dressings not available or prescribable in Primary Care. Where a medicine has been classified as Amber E, but an approved shared-care guideline is not yet available   

Amber

Medicines which can be prescribed within Secondary Care, but are only suitable for prescribing in Primary Care after specialist referral. There is no need for approved shared care guidelines for medicines in this category. This replaces Amber 2 on the North Staffs Formulary.   

Amber E

Medicines which can be prescribed within Secondary Care, but are only considered suitable for prescribing in Primary Care under an approved shared-care agreement (ESCA) or Rationale for Initiation, Continuation and Discontinuation (RICaD). This replaces Amber 1 on the North Staffs Formulary  

Green

Medicines which can be prescribed in either Primary or Secondary Care.  

Grey

These medicines have been reviewed by the New Medicines Committee and the Area Prescribing Committee and found not to be suitable for inclusion in the Joint Formulary. Inadequate or weak evidence for efficacy No clearly defined local need Lack of long term safety data No perceived benefit over established formulary alternatives Prescribers can consider these medicines where formulary alternatives are unsuitable, ineffective or not tolerated.  

netFormulary